CONFIDENTIAL TREATMENT MANUFACTURING AND SUPPLY AGREEMENTConfidential Treatment Manufacturing and Supply Agreement • November 4th, 2005 • Cubist Pharmaceuticals Inc • Pharmaceutical preparations • England
Cubist is a drug company focused on the discovery, development and commercialization of novel drugs to treat infections. Cubist has commenced Phase III clinical trials of its lead product, Daptomycin, an agent with potential bactericidal activity against life threatening infections. DSM has expertise in the manufacture of drugs on a contract basis. DSM is willing to manufacture Daptomycin for Cubist and to sell clinical and commercial quantities of Daptomycin to Cubist. This Agreement sets forth the terms under which DSM will manufacture and supply Daptomycin exclusively to Cubist.
ContractConfidential Treatment Manufacturing and Supply Agreement • May 5th, 2020 • Dublin
<DOCUMENT> <TYPE>EX-10.70 <SEQUENCE>4 <FILENAME>a2122057zex-10_70.txt <DESCRIPTION>EXHIBIT 10.70 <TEXT> <Page> Exhibit 10.70 CONFIDENTIAL TREATMENT MANUFACTURING AND SUPPLY AGREEMENT This Manufacturing and Supply Agreement (the "SUPPLY AGREEMENT") is entered into effective as of October 2, 2003 (the "EFFECTIVE DATE") by and between CHIRON HEALTHCARE IRELAND LTD, a company organized under the laws of Ireland with offices at United Drug House, Belgard Road, Tallaght, Dublin, Ireland ("CHIRON") and CUBIST PHARMACEUTICALS, INC., a Delaware corporation with its principal offices at 65 Hayden Avenue, Lexington, MA 02421 ("CUBIST"). Chiron and Cubist are each sometimes referred to herein individually as a "PARTY" and, collectively, as the "PARTIES." CHIRON CORPORATION, a Delaware corporation having its principal place of business at 4560 Horton Street, Emeryville, California 94608 (the "CHIRON PARENT COMPANY"), is a party to this Supply Agreement only with respect to certain selected provisio
